The Medical Letter on Drugs and Therapeutics
ADVANCE
RELEASE
ARTICLE
In Brief: New Warning for GLP-1 Receptor Agonists
PDF:   US English
Disclosures
Objective(s)
Med Lett Drugs Ther. 2026 Nov 16;68(5135):1   doi:10.58347/tml.2026.5135a

The FDA is requiring that a warning about a risk of nonarteritic anterior ischemic optic neuropathy (NAION) be added to the package inserts of the GLP-1 receptor agonists dulaglutide (Trulicity), exenatide, liraglutide (Saxenda, Victoza), semaglutide (Ozempic, Rybelsus, Wegovy), and orforglipron (Foundayo) and the dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonist tirzepatide (Mounjaro, Zepbound).1

NAION — NAION is caused by reduced blood flow to the optic nerve. It is a common cause of acute optic nerve injury in adults >50 years old (incidence is 2.3-10.2 cases per 100,000 person-years).2 Patients typically present with sudden, painless vision loss in one eye, accompanied by reduced visual acuity and visual field defects. Vision loss can be permanent.3 Patients with a history of NAION are at increased risk of recurrence.

MECHANISM — The mechanism by which GLP-1 receptor agonists increase the risk of NAION is unclear. It may involve rapid correction of hyperglycemia, but patients receiving GLP-1 receptor agonists usually have NAION risk factors, such as diabetes, obesity, cardiovascular disease, hypertension, hyperlipidemia, and obstructive sleep apnea (GLP-1 receptor agonists are FDA-approved for treatment of type 2 diabetes, weight management, obstructive sleep apnea, and cardiovascular risk reduction).3

BASIS FOR NEW WARNING — NAION has been reported with all currently available GLP-1 receptor agonists.4 The new warning was based on the results of a FDA-conducted metaanalysis of 126 randomized controlled trials that included a total of 134,253 patients that found a higher incidence of NAION in GLP-1 receptor agonist users than in nonusers (6.4 cases per 100,000 person-years vs 3.8 cases per 100,000 person-years with placebo or a non-GLP-1 receptor agonist glucose-lowering drug). A retrospective study of data from the FDA Sentinel System that included new users of GLP-1 receptor agonists, sodium-glucose cotransporter 2 (SGLT2) inhibitors, and dipeptidyl peptidase-4 (DPP-4) inhibitors found that the risk of developing NAION with a GLP-1 receptor agonist was not statistically significantly higher compared with a SGLT2 inhibitor, but it was higher compared with a DPP-4 inhibitor (32 events with a GLP-1 receptor agonist vs 31 events with a SGLT2 inhibitor vs 26 events with a DPP-4 inhibitor).1

RECOMMENDATIONS — The new FDA warning advises clinicians to instruct patients receiving GLP-1 receptor agonists to immediately report sudden onset of acute, painless, decreased vision, visual field deficits, or other visual disturbances. Patients with suspected NAION should be promptly referred to an ophthalmologist; the benefits of continuing a GLP-1 receptor agonist should be weighed against the risk of NAION.1 The American Academy of Ophthalmology and the North American Neuro-Ophthalmology Society support the FDA's recommendations.5

  1. FDA Drug Safety Communication. FDA requires safety labeling changes for glucagon-like peptide-1 receptor agonists (GLP-1 RAs) due to potential increased risk of rare but serious eye condition. November 9, 2026. Available at: https://bit.ly/3UFqz32. Accessed November 12, 2026.
  2. SW DeParis et al. Glucagon-like peptide-1 receptor agonists and the risk of non-arteritic anterior ischemic optic neuropathy: a consensus statement by the North American Neuro-Ophthalmology Society and the American Academy of Ophthalmology. Ophthalmology 2026; 133:1029. doi:10.1016/j.ophtha.2026.04.008
  3. OH Ababneh et al. Nonarteritic anterior ischemic optic neuropathy: review and update. Neurol Clin 2026; 44:169. doi:10.1016/j.ncl.2025.11.001
  4. JT Hathaway et al. Risk of nonarteritic anterior ischemic optic neuropathy in patients prescribed semaglutide. JAMA Ophthalmol 2024; 142:732. doi:10.1001/jamaophthalmol.2024.2296
  5. American Academy of Ophthalmology. Here's what you need to know about the FDA's new GLP-1 warning. News release. November 11, 2026. Available at: https://bit.ly/4zlhFWu. Accessed November 13, 2026.
© The Medical Letter, Inc. All Rights Reserved.
The Medical Letter, Inc. does not warrant that all the material in this publication is accurate and complete in every respect. The Medical Letter, Inc. and its editors shall not be held responsible for any damage resulting from any error, inaccuracy, or omission.
This article has been freely provided.